CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
AZD1981 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00766415
NCT00766415Phase 2Completed

A Double-blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca·interventional·Posted Oct 6, 2008·Updated Feb 28, 2014

In Brief

A Phase 2 clinical trial evaluating AZD1981 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 52 participants across 8 sites in 3 countries.

Detailed Summary

The purpose of this study is to study histological changes, cellularity, clinical efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Netherlands, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 6, 2008
Enrollment StartNov 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Posted 17.7 years ago

Interventions

AZD1981drug

Oral tablet, twice daily, 4 weeks treatment

Placebodrug

Placebo